Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TMO
stocks logo

TMO

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
10.68B
+1.3%
5.293
-1.43%
10.84B
+2.28%
5.570
+5.5%
11.78B
+3.38%
6.397
+4.88%
Estimates Revision
The market is revising Downward the revenue expectations for Thermo Fisher Scientific Inc. (TMO) for FY2025, with the revenue forecasts being adjusted by -0.53% over the past three months. During the same period, the stock price has changed by -19.10%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.53%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.69%
In Past 3 Month
Stock Price
Go Down
down Image
-19.10%
In Past 3 Month
20 Analyst Rating
up Image0
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 562.95 USD with a low forecast of 475.00 USD and a high forecast of 637.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
up Image0
Current: 430.925
sliders
Low
475.00
Averages
562.95
High
637.00
up Image0
Current: 430.925
sliders
Low
475.00
Averages
562.95
High
637.00
Argus Research
David Toung
Strong Buy
Maintains
$620 → $470
2025-04-29
Reason
Argus Research
David Toung
Price Target
$620 → $470
2025-04-29
Maintains
Strong Buy
Reason
Argus lowered the firm's price target on Thermo Fisher to $470 from $620 but keeps a Buy rating on the shares. Excluding the academic and government sector, the company's end market conditions are improving as the biopharma industry develops new biologic medicines, the analyst tells investors in a research note. Thermo Fisher is also navigating headwinds arising from trade tariffs and policy changes from the U.S. administration, Argus adds.
Scotiabank
Sung Ji Nam
Hold
Maintains
$650 → $605
2025-04-25
Reason
Scotiabank
Sung Ji Nam
Price Target
$650 → $605
2025-04-25
Maintains
Hold
Reason
Scotiabank lowered the firm's price target on Thermo Fisher to $605 from $650 and keeps a Sector Perform rating on the shares. While it is not yet clear whether the potential pharma tariffs could become material headwinds for the company, but the firm believes Thermo Fisher remains well positioned to mitigate additional risks while capitalizing on long-term growth opportunities, the analyst tells investors.
Baird
Catherine Schulte
Buy
Maintains
$603 → $573
2025-04-24
Reason
Baird
Catherine Schulte
Price Target
$603 → $573
2025-04-24
Maintains
Buy
Reason
Baird lowered the firm's price target on Thermo Fisher to $573 from $603 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company lowered its 2025 revenue and earnings guidance.
Wells Fargo
Brandon Couillard
Buy
Maintains
$580 → $570
2025-04-24
Reason
Wells Fargo
Brandon Couillard
Price Target
$580 → $570
2025-04-24
Maintains
Buy
Reason
Evercore ISI Group
Vijay Kumar
Buy
Maintains
$585 → $500
2025-04-24
Reason
Evercore ISI Group
Vijay Kumar
Price Target
$585 → $500
2025-04-24
Maintains
Buy
Reason
Stifel
Daniel Arias
Strong Buy
Maintains
$665 → $620
2025-04-24
Reason
Stifel
Daniel Arias
Price Target
$665 → $620
2025-04-24
Maintains
Strong Buy
Reason
Stifel lowered the firm's price target on Thermo Fisher to $620 from $665 and keeps a Buy rating on the shares. Thermo "performed well" in Q1 and the company looks to be in good shape to manage through end market and tariff headwinds effectively, though policy changes being pushed "will be tangible when it comes to the P&L," the analyst tells investors in a post-earnings note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO.N) is 18.83, compared to its 5-year average forward P/E of 24.39. For a more detailed relative valuation and DCF analysis to assess Thermo Fisher Scientific Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PE
24.39
Current PE
18.83
Overvalued PE
27.00
Undervalued PE
21.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average EV/EBITDA
20.83
Current EV/EBITDA
16.39
Overvalued EV/EBITDA
22.80
Undervalued EV/EBITDA
18.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
5.07
Current PS
3.44
Overvalued PS
5.60
Undervalued PS
4.54

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased306.25%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

TMO News & Events

Events Timeline

(ET)
2025-04-24
08:22:49
Thermo Fisher to invest $2B in U.S. manufacturing
select
2025-04-23 (ET)
2025-04-23
09:09:55
Thermo Fisher sees Q2 adjusted EPS $5.20-$5.25, consensus $5.73
select
2025-04-23
08:44:31
Thermo Fisher cuts FY25 adjusted EPS view to $21.76-$22.84 from $23.10-$23.50
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
05-13NASDAQ.COM
TMO Quantitative Stock Analysis

  • Thermo Fisher Scientific Analysis: Thermo Fisher Scientific Inc. (TMO) receives a 62% rating from Validea's Low PE Investor model, indicating strong potential based on its earnings growth and valuation in the Medical Equipment & Supplies industry.

  • John Neff's Investment Strategy: John Neff, known for his conservative investment approach, achieved an impressive average annual return of 13.7% over three decades, significantly outperforming the S&P 500 during his tenure managing the Windsor Fund.

Preview
1.0
05-13NASDAQ.COM
Thermo Fisher Scientific To Present At BofA Securities Health Care Conference; Webcast At 11:40 AM

  • Event Announcement: Thermo Fisher Scientific will present at the BofA Securities Health Care Conference on May 13, 2025, at 11:40 AM ET.

  • Webcast Access: The live webcast can be accessed through Thermo Fisher's investor relations website.

Preview
3.0
05-07NASDAQ.COM
TMO Factor-Based Stock Analysis

  • Thermo Fisher Scientific Analysis: Thermo Fisher Scientific Inc. (TMO) receives a 62% rating from Validea's Low PE Investor model, indicating strong potential based on its earnings growth and valuation in the Medical Equipment & Supplies industry.

  • John Neff's Investment Strategy: John Neff, known for his conservative investment approach, achieved an impressive average annual return of 13.7% over three decades, significantly outperforming the S&P 500 during his tenure managing the Windsor Fund.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Thermo Fisher Scientific Inc (TMO) stock price today?

The current price of TMO is 430.925 USD — it has decreased -0.38 % in the last trading day.

arrow icon

What is Thermo Fisher Scientific Inc (TMO)'s business?

Thermo Fisher Scientific Inc. is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. The Company's Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Analytical Instruments segment provides instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory.

arrow icon

What is the price predicton of TMO Stock?

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 562.95 USD with a low forecast of 475.00 USD and a high forecast of 637.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Thermo Fisher Scientific Inc (TMO)'s revenue for the last quarter?

Thermo Fisher Scientific Inc revenue for the last quarter amounts to 10.36B USD, increased 0.18 % YoY.

arrow icon

What is Thermo Fisher Scientific Inc (TMO)'s earnings per share (EPS) for the last quarter?

Thermo Fisher Scientific Inc. EPS for the last quarter amounts to 3.98 USD, increased 15.03 % YoY.

arrow icon

What changes have occurred in the market's expectations for Thermo Fisher Scientific Inc (TMO)'s fundamentals?

The market is revising Downward the revenue expectations for Thermo Fisher Scientific Inc. (TMO) for FY2025, with the revenue forecasts being adjusted by -0.53% over the past three months. During the same period, the stock price has changed by -19.10%.
arrow icon

How many employees does Thermo Fisher Scientific Inc (TMO). have?

Thermo Fisher Scientific Inc (TMO) has 122000 emplpoyees as of May 14 2025.

arrow icon

What is Thermo Fisher Scientific Inc (TMO) market cap?

Today TMO has the market capitalization of 163.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free